Company Update (NASDAQ:CELG): Celgene to Present Long-Term Efficacy and Safety Data on Oral OTEZLA® (apremilast) in Plaque Psoriasis and Psoriatic Arthritis at European Academy of Dermatology and Venereology Congress

[Business Wire] – Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation , today announced that the latest research findings on OTEZLA® , the Company’s oral, selective inhibitor of phosphodiesterase 4 , in . . . → Read More: Company Update (NASDAQ:CELG): Celgene to Present Long-Term Efficacy and Safety Data on Oral OTEZLA® (apremilast) in Plaque Psoriasis and Psoriatic Arthritis at European Academy of Dermatology and Venereology Congress Similar Articles: Stock Update: Celgene Corporation (NASDAQ:CELG) – Celgene Corporation to Present at Investor Conferences in September Company Update: Celgene Corporation (NASDAQ:CELG) – Celgene Corporation to Present at Investor Conferences in June Stock Update (NASDAQ:CELG): Celgene Corporation to Present at Investor Conferences in May